These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19576622)

  • 1. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
    Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
    Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
    Westfall SD; Skinner MK
    Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
    Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
    Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of triptolide as an adjunct chemotherapy for ovarian cancer.
    Westfall SD; Nilsson EE; Skinner MK
    Chemotherapy; 2008; 54(1):67-76. PubMed ID: 18073474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
    Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
    Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
    J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
    Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
    Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
    Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
    Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
    Arafa el-SA; Zhu Q; Barakat BM; Wani G; Zhao Q; El-Mahdy MA; Wani AA
    Cancer Res; 2009 Dec; 69(23):8910-7. PubMed ID: 19903849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
    Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.